



49th Annual Meeting of the EBMT



Sunday, April 23, 2023

2:30 p.m.–4:00 p.m.

Palais des Congrès de Paris

Room 151 / Virtual Meeting Platform

AGENDA

- Chair:** Christian Chabannon, Marseille, France
- 2:30 p.m.** Welcome & introduction
Christian Chabannon, Marseille, France
- 2:40 p.m.** Use of TCR $\alpha\beta$ /CD19-depleted grafts from HLA-haploidentical donors for the treatment of non-malignant disorders: is it the new black?
Pietro Merli, Rome, Italy
- 3:00 p.m.** Safety and efficacy of high-dose of memory (CD45RA⁻-depleted) donor lymphocyte infusion in pediatric recipients after hematopoietic stem cell transplantation
Antonio Perez, Madrid, Spain
- 3:20 p.m.** What is the future for academic CAR T manufacture?
Claire Roddie, London, UK
- 3:40 p.m.** Zamtocabtagene autoleucl – A non-cryopreserved tandem-CAR T cell product targeting CD19 and CD20 in B cell non-Hodgkin lymphoma (B-NHL)
Christof Scheid, Cologne, Germany

Cell therapy: latest advances and future visions

Miltenyi Biotec Satellite Symposium

► miltenyibiotec.com

The statements and other contributions presented at the meeting and the views expressed therein are those of the attending experts and do not necessarily represent the policy or opinion of Miltenyi Biotec or any institution the respective expert may be associated with. Neither Miltenyi Biotec nor any of its directors or employees give any representation or warranty as to the reliability, accuracy, or completeness of the content thereof. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This notice must accompany any further distribution of this document. Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. For further regulatory notes, refer to miltenyibiotec.com/regulatory-notes. CliniMACS, CliniMACS Prodigy, MACS, and the Miltenyi Biotec logo are registered trademarks or trademarks of Miltenyi Biotec and/or its affiliates in various countries worldwide. Copyright © 2023 Miltenyi Biotec and/or its affiliates. All rights reserved.



Miltenyi Biotec